Almac
Private Company
Funding information not available
Overview
Almac Group is a large, privately-held, revenue-generating CDMO and service provider with a significant global footprint. The company has demonstrated strong growth, surpassing £1 billion in revenue, and supports approximately 50% of approved new molecular entities (NMEs). Its business model is centered on providing comprehensive, outsourced services including drug discovery, diagnostic development, clinical trial supply management, and pharmaceutical manufacturing. Recent multi-million-pound investments in new facilities and technologies underscore its expansion strategy and commitment to sustainability.
Technology Platform
Provider of integrated service platforms across drug discovery, diagnostic development, clinical trial technology, and pharmaceutical manufacturing.
Opportunities
Risk Factors
Competitive Landscape
Operates in the highly competitive global CDMO and pharmaceutical services sector, competing with large public players like Lonza and Catalent, as well as numerous specialized service providers. Its key differentiator is its fully integrated, end-to-end service model across the drug development lifecycle.